Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.

Oncoimmunology - 1 Jan 2021

Dillard Pierre, Casey Nicholas, Pollmann Sylvie, Vernhoff Patrik, Gaudernack Gustav, Kvalheim Gunnar, Wälchli Sébastien, Inderberg Else Marit

Abstract excerpt

T-cell receptor (TCR) redirected T cells are considered as the next generation of care for the treatment of numerous solid tumors. KRAS mutations are driver neoantigens that are expressed in over 25% of all cancers and are thus regarded as ideal targets for Adoptive Cell Therapy (ACT). We have isolated four KRAS-specific TCRs from a long-term surviving pancreatic cancer patient vaccinated with a mix of mutated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigens, Neoplasm
Share to HLA Antigens

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Mutation

Share to Pancreatic Neoplasms

Share to Proto-Oncogene Proteins p21(ras)

Share to Receptors, Antigen, T-Cell

Source

Open in PubMed Open full text

Identifiers

PMID: 34235003
DOI: 10.1080/2162402X.2021.1936757
PMCID: PMC8216182

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting KRAS mutations with HLA class II-restricted TCRs for the treatment of solid tumors.PMID 34235003Read ↗

Targeting KRASG12V mutations with HLA class II-restricted TCR for the immunotherapy in solid tumors.Semantic proximity Read ↗

KRAS G12V neoantigen specific T cell receptor for adoptive T cell therapy against tumorsSemantic proximity Read ↗

Natural TCRs targeting KRASG12V display fine specificity and sensitivity to human solid tumorsSemantic proximity Read ↗

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognition.Semantic proximity Read ↗

Systematic discovery and validation of T cell targets directed against oncogenic KRAS mutations.Semantic proximity Read ↗

Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients.Semantic proximity Read ↗

Recombinant T cell receptors specific for HLA-A*02:01-restricted neoepitopes containing KRAS codon 12 hotspot mutationsSemantic proximity Read ↗

Targeting mutated KRAS by HLA-A*02:01 restricted anti-KRAS TCR-mimic CAR and bispecific T cell engager.Semantic proximity Read ↗

Identification and affinity enhancement of T-cell receptor targeting a KRASG12V cancer neoantigen.Semantic proximity Read ↗

Identification of novel KRASG12D neoantigen specific TCRs and a strategy to eliminate off-target recognitionSemantic proximity Read ↗

Mutant KRAS peptide targeted CAR-T cells engineered for cancer therapy.Semantic proximity Read ↗

Dual-degenerate TCRs target multiple KRAS hotspot and HLA-A3 family combinationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.